JPRN-UMIN000001067已完成未知
An open-label, randomized, controlled study of treatment duration of peginterferon alpha-2a monotherapy in patients with chronic hepatitis C - A randomized trial of peginterferon alpha-2a for chronic hepatitis C
Japanese Consortium for the Study of Liver Diseases0 个研究点目标入组 270 人开始时间: 2008年3月31日最近更新:
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 270
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •The following patients were excluded. 1. Concomitant herbal medication of Sho-saiko-to 2. Autoimmune hepatitis, alcoholic liver injury, or chronic liver diseases with other underlying causes 3. Allergic to pegylated interferon alpha-2a or other interferon preparations 4. Allergic to vaccine or biological preparations 5. Liver cirrhosis, decompensated liver disease, hepatocellular carcinoma, or other malignant diseases 6. Depression or psychiatric disorders 7. Other conditions considered inappropriate by attending physician
研究者
相似试验
已完成
2 期
Role of Yacrujjay tablet in Patients with Non-Alcoholic Fatty Liver Disease (NAFLD)CTRI/2022/12/047884Dean and Principal Parul Institute of Ayurved
进行中（未招募）
1 期
Open-label clinical trial with an open-label extension to investigate the safety of BMN 111 in infants and young children with achondroplasiaMedDRA version: 20.0Level: LLTClassification code 10000452Term: AchondroplasiaSystem Organ Class: 100000004850achondroplasiaEUCTR2020-001055-40-GBBioMarin Pharmaceutical Inc.20
尚未招募
2 期
To access nutritional effect of dates in pregnancyCTRI/2024/06/068860Sanika Ashok Ghaiwat
进行中（未招募）
1 期
clinical trial to assess the safety, tolerability and efficacy of two dolutegravir-based simplification strategies in HIV-infected patients with prolonged virological suppression.Infection with human immunodeficiency virus (HIV).MedDRA version: 20.1Level: LLTClassification code 10008919Term: Chronic HIV infectionSystem Organ Class: 100000004862EUCTR2015-000274-35-ESFUNDACIÓ CLÍNIC PER A LA RECERCA BIOMÈDICA265
进行中（未招募）
1 期
A randomized, exploratory, open-label 48-week trial with a 2-week Pre-Treatment Phase to investigate the pharmacokinetics, safety, tolerability and antiviral activity of etravirine (ETR) in combination with ritonavir-boosted atazanavir (ATV/rtv) and 1 NRTI in treatment-experienced HIV-1 infected subjectsEUCTR2009-010887-41-FRTibotec Pharmaceuticals